SKIN-CAD – Biocom Systems, Inc.

Biocom Systems is a developer of SKIN-CAD, the only simulation software for transdermal and topical drug delivery.

›
Activity

Latest Research Publication on SKIN-CAD

  • D.Mori1, T.Kugimiya2, A.Harada2, T.Hikima2 (1Biocom Systems, Inc., 2Kyushu Institute of Technology)
    in vitro – in silico Prediction of Blood Concentration in Human Following Transdermal Drug Delivery
    Poster presentation at 30th Annual Meeting of the Japan Society of Drug Delivery System
    Tokyo, July 30-31, 2014.

  • D.Mori1, T.Kugimiya2, A.Harada2, T.Hikima2 (1Biocom Systems, Inc., 2Kyushu Institute of Technology)
    Human Pharmacokinetic Simulation of Percutaneous Absorption Using in vitro Animal Skin Permeation Data
    Poster presentation at 29th Annual Meeting of the Academy of Pharmaceutical Science and Technology, Japan
    Saitama, May 20-22, 2014.

 

 

 

SKIN-CAD Users and Publications

[SKIN-CAD total users]

  • Kyushu Institute of Technology and National Cancer Center (limited term user)
  • 13 Japanese companies including Hisamitsu Pharmaceuticals Co., Inc. and Taisho Pharmaceuticals Co., Ltd.
  • Loughborough University (UK) and Oxford University (UK)
  • 2 European pharmaceutical companies and 1 US pharmaceutical company

[SKIN-CAD publications]

  1. Iwao, Y.1; Matsuoka, K.1; Okada, K.1; Minami, K.2; Yuasa, S.2 (1 Nitto Denko Corporation, 2 Toa Eiyo Ltd.) Percutaneous administration device of bisoprolol, US 8703178 B2, 2014.
  2. Hikima, T.1; Komatsu, M.1; Mori, D.2; Tojo, K.1 (1 Kyushu Institute of Technology, 2 Biocom Systems, Inc.) Prediction of Percutaneous Absorption in Human of Nicotine from Marketed TTS using Three-dimensional Human Cultured Epidermis, 40th Annual Meeting & Exposition of the Controlled Release Society, Honolulu, Hawaii, July 21-24, 2013.
  3. Saeki, Y.; Nishimura, M.; Matsuoka, K.; Muraoka, T.; Hosaka, Y.; Hori, M.; Ninomiya, K.; Akemi, H.; Kuroda, H. (Nitto Denko Corporation) Adhesive preparation containing fentanyl, US 8591939 B2, 2013.
  4. Hikima, T.; Kaneda, N.; Matsuo, K.; Tojo, K. (Kyushu Institute of Technology) Prediction of percutaneous absorption in human using three-dimensional human cultured epidermis LabCyte EPI-MODEL, Biol. Pharm. Bull. 2012, 35(3), 362-368.
  5. Nakamura, A.1,2; Mori, D.3; Tojo, K.1 (1 Kyushu Institute of Technology, 2 Yutoku Pharmaceutical Industries Co., Ltd., 3 Biocom Systems, Inc.) Evaluation of the predicted time-concentration profile of serum tulobuterol in human after transdermal application, Chem. Pharm. Bull. 2012, 60(3), 300-305.
  6. Olatunji, O.; Das, D.B.; Nassehi, V. (Loughborough University) Modelling transdermal drug delivery using microneedles: Effect of geometry on drug transport behaviour, J. Pharm. Sci. 2012, 101(1), 164-175.
  7. Tominaga, K.1,2; Tojo, K.1 (1 Kyushu Institute of Technology, 2 Kyoritsu Pharmaceutical Industries Co., Ltd.) Effect of environmental temperature on transdermal drug penetration, Biol. Pharm. Bull. 2010, 33(12), 1983-1987.
  8. Amano, S.; Honma, S.; Tateishi, T. (Hisamitsu Pharmaceutical Co., Inc.) Patch, US20100227932 A1, 2010.
  9. Yoshitake, M.; Ga, K. (Yutoku Pharmaceutical Industries Co., Ltd.) Riluzole-containing transdermal patch, WO2010113225 A1, 2010.
  10. Tojo, K.; Kimura, C. (Kyushu Institute of Technology) Solid Ophthalmic Drug for External Use, US 20100160293 A1, 2010.
  11. Al-Qallaf, B.1; Mori, D.3; Olatunji, L.2; Das, D.B.2; Cui, Z.1 (1 Oxford University, 2 Loughborough University, 3 Biocom Systems, Inc.) Transdermal drug delivery by microneedles: Does skin metabolism matter? Int. J. Chem. React. Eng. 2009, 7, A69 (pp.1-23).
  12. Olatunji, O.1; Das, D.B.1; Al-Qallaf, B.2 (1 Loughborough University, 2 Oxford University) Simulation based optimization of microneedle geometry to improve drug permeability in skin, 7th Annual Industrial Simulation Conference (ISC’2009), Loughborough, UK, June 1-3, 2009.
  13. Al-Qallaf, B.1; Das, D.B.2; Davidson, A.1 (1 Oxford University, 2 Loghborough University) Transdermal drug delivery by coated microneedles: geometry effects on drug concentration in blood, Asia-Pacific J. Chem. Eng. 2009, 4(6), 845-857.
  14. Al-Qallaf, B.1; Das, D.B.2 (1 Oxford University, 2 Loughborough University) Optimization of square microneedle arrays for increasing drug permeability in skin, Chem. Eng. Sci. 2008, 63, 2523-2535.
  15. Kimura, C.; Tojo, K. (Kyushu Institute of Technology) Stick-type transdermal delivery system for ocular diseases, 2007 AAPS Annual Meeting and Exposition, San Diego, CA, November 10-15, 2007.
  16. Tojo, K.; Hikima, T. (Kyushu Institute of Technology) Bioequivalence of marketed transdermal delivery systems for tulobuterol, Biol. Pharm. Bull. 2007, 30(8), 1576-1579.
  17. Al-Qallaf, B.1; Das, D.B.1; Mori, D.2; Cui, Z.1 (1 Oxford University, 2 Biocom Systems, Inc.) Modelling transdermal delivery of high molecular weight drugs from microneedle systems, Phil. Trans. R. Soc. A 2007, 365(1861), 2951–2967.
  18. Kimura, C.; Tojo, K. (Kyushu Institute of Technology) Development of a stick-type transdermal eyelid delivery system of ketotifen fumarate for ophthalmic diseases, Chem. Pharm. Bull. 2007, 55(7), 1002-1005.
  19. Mori, D.1; Tojo, K.2 (1 Biocom Systems, Inc., 2 Kyushu Institute of Technology) SKIN-CAD®: Pharmacokinetic model for transdermal drug delivery, 2006 AIChE Annual Meeting, San Francisco, CA, November 12-17, 2006.
  20. Terahara, T.; Toshimitsu, A.; Uemura, K.; Higo, N.; Goto, T.; Sato, S. (Hisamitsu Pharmaceutical Co., Inc.) Percutaneous absorption preparations, US 20040258741 A1, 2004.
  21. Isowaki, A.1; Ohtori, A.1; Matsuo, Y.2; Tojo, K.2 (1 Senju Pharmaceutical Co., Ltd., 2 Kyushu Institute of Technology) Drug delivery to the eye with a transdermal therapeutic system, Biol. Pharm. Bull. 2003, 26(1), 69-72.
  22. Mori, D.1; Kawamata, H.1,2; Tojo, K.1 (1 Kyushu Institute of Technology, 2 Taiho Pharmaceutical Co., Ltd.) Drug concentration – time profile in the plasma following the dissolution-type transdermal delivery, J. Chem. Eng. Japan 2003, 36(1), 45-48.
  23. Mori, D.; Tojo, K. (Kyushu Institute of Technology) In silico evaluation for skin pharmacokinetics, 29th Annual Meeting & Exposition of the Controlled Release Society, Seoul, Korea, July 20-25, 2002.
  24. Kawamata, H.1,2; Tojo, K.1 (1 Kyushu Institute of Technology, 2 Taiho Pharmaceutical Co., Ltd.) Prediction of plasma concentration of GTS-21 in hairless rats following monolithic transdermal delivery, Biol. Pharm. Bull. 2002, 25(3), 342-345.

 

 

Poster Presentation at 40th CRS Annual Meeting – July, 2013

(Poster #915)

Prediction of Percutaneous Absorption in Human of Nicotine from Marketed TTS using Three-dimensional Human Cultured Epidermis.

T. Hikima 1), M. Komatsu 1), D. Mori 2), and K. Tojo 1)
1) Kyushu Institute of Technology, 2) Biocom Systems, Inc.

40th Annual Meeting & Exposition of the Controlled Release Society, July 21-24, 2013, Hawaii Convention Center, Honolulu, Hawaii, U.S.A.